Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 19/20 | 0.69 |
| ▸ | PDE4D | Q08499 | 18/20 | 0.69 |
| ▸ | PDE4A | P27815 | 7/20 | 0.69 |
| ▸ | PDE4C | Q08493 | 7/20 | 0.69 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.69 |
| ▸ | GCK | P35557 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4544198 | 0.82 | PDE4B (0.71) | PDE4BPDE4DPDE4APDE4CABCB11 | |
| SCHEMBL2887750 | 0.82 | PDE4B (0.92) | PDE4BPDE4DPDE4APDE4CABCB11 | |
| Roflumilast SCHEMBL18095182 | 0.82 | PDE4B (1.00) | PDE4BPDE4DPDE4APDE4CABCB11 | |
| Roflumilast SCHEMBL29349467 | 0.82 | PDE4B (1.00) | PDE4BPDE4DPDE4APDE4CABCB11 | |
| SCHEMBL30084829 | 0.82 | PDE4B (0.92) | PDE4BPDE4DPDE4APDE4CABCB11 | |
| Roflumilast SCHEMBL19158 | 0.82 | PDE4B (1.00) | PDE4BPDE4DPDE4APDE4CABCB11 | |
| Roflumilast SCHEMBL29033058 | 0.81 | PDE4B (0.98) | PDE4BPDE4DPDE4APDE4CABCB11 | |
| Roflumilast SCHEMBL28150332 | 0.81 | PDE4B (0.98) | PDE4BPDE4DPDE4APDE4CABCB11 | |
| Roflumilast SCHEMBL29039838 | 0.81 | PDE4B (0.98) | PDE4BPDE4DPDE4APDE4CABCB11 | |
| SCHEMBL5161562 | 0.81 | PDE4D (0.62) | PDE4BPDE4DPDE4APDE4CABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110224128-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF MUSCULAR DYSTROPHY | WHALEN ANNE | 2011-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224128-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF MUSCULAR DYSTROPHY | PYGM, TNNC1, MYOF | PDE4B 122/4885PDE4D 261/4885PDE4A 106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.